UroGen Pharma's Retrospective Study Finds JELMYTO Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma Ltd. (NASDAQ:URGN) has published the results of a sub-analysis from the first post-commercial utilization review of JELMYTO (mitomycin) for pyelocalyceal solution. The study assessed the efficacy of JELMYTO in managing patients with larger volume disease where initial tumor burden may not be amenable to complete mechanical ablation or renal preservation.
July 10, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from UroGen Pharma's study on JELMYTO could potentially boost the company's reputation and stock.
The positive results from the study on JELMYTO, a product of UroGen Pharma, could potentially increase the company's reputation in the market. This could lead to an increase in the company's stock as investors may see this as a sign of the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100